London (UK) June 10th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), Vidac Pharma, a clinical-stage biopharmaceutical company developing innovative cancer therapies, is pleased to announce the publication of a new peer-reviewed scientific article that explores the potential of its proprietary compound VDA1275—both as a standalone therapy and in synergistic combination with traditional chemotherapy.
The article, published in A novel chemical entity, that reverses Warburg metabolism by disrupting VDAC1/HK2 interaction through “Toposteric Effect” in Cancer provides an in-depth look at the mechanism of action of VDA1275, a promising new drug candidate for the treatment of solid tumors.
The study highlights VDA1275’s triple mechanism of action:
- Reversal of the Warburg effect: VDA1275 disrupts excessive glycolysis in cancer cells, restoring normal cellular metabolism.
- Reactivation of apoptosis: By reopening the mitochondrial pore, VDA1275 restores programmed cell death pathways that are often disabled in tumors.
- Modulation of the tumor microenvironment (TME): VDA1275 reduces lactate production, creating a more favorable microenvironment that enhances the efficacy of chemotherapeutic agents and promotes a pro-immune response.
This breakthrough adds to Vidac Pharma’s growing oncology pipeline. The company's lead drug candidate, Almavid™ (a proprietary formulation of Tuvatexib (VDA1102)), is currently undergoing advanced development for subcutaneous administration across multiple cancer types.
VDA1275, designed for oral administration, complements Almavid™ and has demonstrated highly synergistic activity when used in combination with classical chemotherapy agents, as detailed in this collaborative research with HCS scientists.
"We are excited to see the promising data on VDA1275’s unique mechanism and its potential to improve outcomes for cancer patients," said Dr. Max Herberg, Active Chairman & CEO at Vidac Pharma. "This study marks an important milestone in our mission to develop therapies that overcome tumor resistance and enhance the effectiveness of existing treatments."
Vidac Pharma remains committed to advancing its innovative oncology programs and bringing new hope to patients worldwide.
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), and in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.